title: Antiemetic activity of oral lorazepam in addition to methylprednisolone and metoclopramide in the prophylactic treatment of vomiting induced by cisplatin. A double-blind, placebo-controlled study with crossover design.
abstract: OBJECTIVE
  It has been suggested that lorazepam has a definite role as an antiemetic drug in antiemetic cocktails. In this study we examined the antiemetic efficacy of metoclopramide (200 mg) and methylprednisolone (1000 mg) with or without lorazepam.
  
  
  METHODS
  Sixty patients treated with cisplatin-containing regimens were entered into a randomized, double-blind study with cross-over. Lorazepam 2.5 mg or placebo were administered orally the evening before therapy and just after the beginning of fluid infusion for chemotherapy. Degree of nausea and number of vomiting episodes, together with somnolence, were recorded on a data flow sheet and visual-analogue scales.
  
  
  RESULTS
  100 cycles (50 patients) are evaluable. In 39 cycles there was no nausea and vomiting, in 74 cycles acceptable control of emesis was reached (0-2 episodes of vomiting), without significant differences among the two arms. However, nausea was shorter in lorazepam arm (p < 0.01), and 80% of the patients preferred treatment with lorazepam (p < 0.003). Anxiety was reduced in the patients treated with lorazepam (p < 0.4).
  
  
  CONCLUSIONS
  Lorazepam improves tolerability to cisplatin-containing chemotherapy, mainly by influencing the psychological status of the patient and favoring the amnestic process.
authors.affiliation: Divisione di Oncologia Medica, Ospedale S. Giovanni Antica Sede, Torino, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Clerico
authors.forename: O
authors.initials: O
authors.lastname: Bertetto
authors.forename: M P
authors.initials: MP
authors.lastname: Morandini
authors.forename: C
authors.initials: C
authors.lastname: Cardinali
authors.forename: G
authors.initials: G
authors.lastname: Giaccone
mesh_terms: D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000009:adverse effects*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000008:administration & dosage*; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D008787:Metoclopramide / Q000008:administration & dosage*; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D008787:Metoclopramide; D008140:Lorazepam; D002945:Cisplatin; D008775:Methylprednisolone